Vivek Arora

Washington University in St. Louis — United States

Medicine · Health Sciences

26h-index13.3kcitations109works0.52yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Bladder and Urothelial Cancer Treatments(38), Prostate Cancer Treatment and Research(19), Tissue Engineering and Regenerative Medicine(18), Urinary and Genital Oncology Studies(17), Epigenetics and DNA Methylation(11)

Publications109 total

Supplementary Table S1 from KDM6A Loss Triggers an Epigenetic Switch That Disrupts Urothelial Differentiation and Drives Cell Proliferation in Bladder Cancer
2025Open Access
Supplementary Figure Legends from KDM6A Loss Triggers an Epigenetic Switch That Disrupts Urothelial Differentiation and Drives Cell Proliferation in Bladder Cancer
2025Open Access
Supplementary Data 1 from KDM6A Loss Triggers an Epigenetic Switch That Disrupts Urothelial Differentiation and Drives Cell Proliferation in Bladder Cancer
2025Open Access
Supplementary Figure 7 from KDM6A Loss Triggers an Epigenetic Switch That Disrupts Urothelial Differentiation and Drives Cell Proliferation in Bladder Cancer
2025Open Access
Supplementary Figure 1 from KDM6A Loss Triggers an Epigenetic Switch That Disrupts Urothelial Differentiation and Drives Cell Proliferation in Bladder Cancer
2025Open Access
Supplementary Figure 8 from KDM6A Loss Triggers an Epigenetic Switch That Disrupts Urothelial Differentiation and Drives Cell Proliferation in Bladder Cancer
2025Open Access
Supplementary Figure 5 from KDM6A Loss Triggers an Epigenetic Switch That Disrupts Urothelial Differentiation and Drives Cell Proliferation in Bladder Cancer
2025Open Access
Supplementary Figure 6 from KDM6A Loss Triggers an Epigenetic Switch That Disrupts Urothelial Differentiation and Drives Cell Proliferation in Bladder Cancer
2025Open Access
Supplementary Figure 4 from KDM6A Loss Triggers an Epigenetic Switch That Disrupts Urothelial Differentiation and Drives Cell Proliferation in Bladder Cancer
2025Open Access
Supplementary Figure 3 from KDM6A Loss Triggers an Epigenetic Switch That Disrupts Urothelial Differentiation and Drives Cell Proliferation in Bladder Cancer
2025Open Access
Supplementary Figure 2 from KDM6A Loss Triggers an Epigenetic Switch That Disrupts Urothelial Differentiation and Drives Cell Proliferation in Bladder Cancer
2025Open Access
Supplementary Data 2 from KDM6A Loss Triggers an Epigenetic Switch That Disrupts Urothelial Differentiation and Drives Cell Proliferation in Bladder Cancer
2025Open Access
Developing Standardized Online Adaptive Automated Templates for Ongoing Clinical Trials: Methodology from the Janus Rectal Cancer Trial
International Journal of Radiation Oncology*Biology*Physics·2025Open Access
Discovery of BMS-986365, a First-in-Class Dual Androgen Receptor Ligand-Directed Degrader and Antagonist, for the Treatment of Advanced Prostate Cancer
Clinical Cancer Research·2025· 5 citedOpen Access
454P Institutional experience of concurrent Doce-aquilip in head and neck cancer patients who are cisplatin ineligible
Annals of Oncology·2024Open Access
1597MO Clinical activity of BMS-986365 (CC-94676), a dual androgen receptor (AR) ligand-directed degrader and antagonist, in heavily pretreated patients (pts) with metastatic castration-resistant prostate cancer (mCRPC)
Annals of Oncology·2024· 3 cited
12. Endothelial cells are a key target of IFN-g during response to combined PD-1/CTLA-4 ICB treatment in bladder cancer
Cancer Genetics·2023
Abstract 6: Comprehensive single-cell transcriptomic analysis of a mouse model of bladder cancer identifies endothelial cells as a principal target of interferon gamma during response to combined PD-1, CTLA-4 immune checkpoint inhibitor treatment
Cancer Research·2023· 2 cited
Supplementary Figure Legends from KDM6A Loss Triggers an Epigenetic Switch That Disrupts Urothelial Differentiation and Drives Cell Proliferation in Bladder Cancer
2023Open Access
Supplementary Data 2 from KDM6A Loss Triggers an Epigenetic Switch That Disrupts Urothelial Differentiation and Drives Cell Proliferation in Bladder Cancer
2023Open Access
page 1 of 6Next →

Frequent Co-authors

Charles L. Sawyers(11), Brian C. Baumann(10), John Wongvipat(9), Eric H. Kim(8), Bruce J. Roth(8), Melissa A. Reimers(7), Zachary L. Smith(7), Benjamin W. Fischer‐Valuck(7), John P. Christodouleas(7), E Knoche(7), Russell K. Pachynski(7), Hiram A. Gay(7), Joel Picus(7), Yu Chen(6), Philip A. Watson(5), Pradeep S. Chauhan(5), Nadja Pejovic(5), Peter K. Harris(5), Aadel A. Chaudhuri(5), Jennifer K. Bolzenius(5)